Eurofins competitors

John Ratliff served as Chief Executive Officer of Covance Drug Development, the world’s most comprehensive drug development company. He is a highly respected biopharmaceutical leader, with extensive experience in increasingly influential roles in the industry. In 2018, Ratliff was appointed Chairman for the Association of Clinical Research Organizations. Previously John was president and CEO of HUYA Bioscience International. His healthcare industry experience also includes almost 10 years at Quintiles, the world’s largest provider of product development and integrated healthcare services, where he served as Chief Financial Officer before becoming President and Chief Operating Officer. He was a member of the Quintiles board of directors. Prior roles throughout his career included CFO at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and positions of increasing responsibility during his 19-year tenure at IBM.

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to several successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace. After earning his doctorate in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.